| Multiple Myeloma |
1 |
1 |
| CAR-T |
0 |
0.99 |
| Biologic Therapy |
0 |
0.91 |
| T-Lymphocyte |
0 |
0.64 |
| Food and Drug Administration (FDA) |
0 |
0.24 |
| Otolaryngology |
0 |
0.22 |
| Antigens |
0 |
0.16 |
| Hematology |
0 |
0.16 |
| Toxicology |
0 |
0.16 |
| Patient Safety |
0 |
0.14 |
| Upper Respiratory Tract Infection |
0 |
0.11 |
| Adverse Effects |
0 |
0.08 |
| Blood |
0 |
0.08 |
| Cough |
0 |
0.08 |
| Cytokines |
0 |
0.08 |
| Dizziness |
0 |
0.08 |
| Dorsum |
0 |
0.08 |
| Dyspnea |
0 |
0.08 |
| Edema |
0 |
0.08 |
| Encephalopathy |
0 |
0.08 |
| Fatigue |
0 |
0.08 |
| Fever |
0 |
0.08 |
| Hypogammaglobulinemia |
0 |
0.08 |
| Hypotension |
0 |
0.08 |
| Immunotherapy |
0 |
0.08 |
| Medical Oncology |
0 |
0.08 |
| Monoclonal Antibody |
0 |
0.08 |
| Nausea |
0 |
0.08 |
| Neurotoxicity |
0 |
0.08 |
| Pain |
0 |
0.08 |
| Parkinsonian |
0 |
0.08 |
| Proteasome Inhibitor |
0 |
0.08 |
| Receptors |
0 |
0.08 |
| Remission |
0 |
0.08 |
| Respiratory Tract |
0 |
0.08 |
| Risk Evaluation and Mitigation Strategies |
0 |
0.08 |
| Tachycardia |
0 |
0.08 |
| Targeted Cancer Therapy |
0 |
0.08 |
| Viral Infection |
0 |
0.08 |
| Arrhythmia |
0 |
0.07 |
| Constipation |
0 |
0.07 |
| Diarrhea |
0 |
0.07 |
| Headache |
0 |
0.07 |
| Pain Management |
0 |
0.07 |
| Parkinson Disease |
0 |
0.07 |
| Revenue and Practice Management |
0 |
0.07 |